Frontiers in Immunology (Sep 2023)

Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis

  • Yang Shu,
  • Yang Shu,
  • Wei Xu,
  • Wei Xu,
  • Rui Su,
  • Pancen Ran,
  • Pancen Ran,
  • Lei Liu,
  • Zhizhao Zhang,
  • Jing Zhao,
  • Zhen Chao,
  • Guobin Fu,
  • Guobin Fu,
  • Guobin Fu,
  • Guobin Fu

DOI
https://doi.org/10.3389/fimmu.2023.1251645
Journal volume & issue
Vol. 14

Abstract

Read online

Immune checkpoint inhibitors (ICIs) modulate the body’s immune function to treat tumors but may also induce pneumonitis. Immune checkpoint inhibitor-related pneumonitis (ICIP) is a serious immune-related adverse event (irAE). Immunotherapy is currently approved as a first-line treatment for non-small cell lung cancer (NSCLC), and the incidence of ICIP in NSCLC patients can be as high as 5%-19% in clinical practice. ICIP can be severe enough to lead to the death of NSCLC patients, but there is a lack of a gold standard for the diagnosis of ICIP. Radiomics is a method that uses computational techniques to analyze medical images (e.g., CT, MRI, PET) and extract important features from them, which can be used to solve classification and regression problems in the clinic. Radiomics has been applied to predict and identify ICIP in NSCLC patients in the hope of transforming clinical qualitative problems into quantitative ones, thus improving the diagnosis and treatment of ICIP. In this review, we summarize the pathogenesis of ICIP and the process of radiomics feature extraction, review the clinical application of radiomics in ICIP of NSCLC patients, and discuss its future application prospects.

Keywords